KOREA PHARMA Co., Ltd. (KOSDAQ:032300)

KOREA PHARMA Statistics

Total Valuation

KOREA PHARMA has a market cap or net worth of KRW 99.58 billion. The enterprise value is 109.90 billion.

Market Cap	99.58B
Enterprise Value	109.90B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 29, 2025

Share Statistics

KOREA PHARMA has 10.91 million shares outstanding. The number of shares has decreased by -0.33% in one year.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	-0.33%
Shares Change (QoQ)	-0.68%
Owned by Insiders (%)	63.38%
Owned by Institutions (%)	0.01%
Float	3.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.09
PB Ratio	1.44
P/TBV Ratio	1.51
P/FCF Ratio	n/a
P/OCF Ratio	19.54
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 48.52, with an EV/FCF ratio of -7.93.

EV / Earnings	-44.45
EV / Sales	1.20
EV / EBITDA	48.52
EV / EBIT	n/a
EV / FCF	-7.93

Financial Position

The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.58.

Current Ratio	1.14
Quick Ratio	0.77
Debt / Equity	0.58
Debt / EBITDA	14.65
Debt / FCF	-2.87
Interest Coverage	-0.11

Financial Efficiency

Return on equity (ROE) is -3.52% and return on invested capital (ROIC) is -0.52%.

Return on Equity (ROE)	-3.52%
Return on Assets (ROA)	-0.21%
Return on Invested Capital (ROIC)	-0.52%
Return on Capital Employed (ROCE)	-0.59%
Weighted Average Cost of Capital (WACC)	7.69%
Revenue Per Employee	682.22M
Profits Per Employee	-18.45M
Employee Count	134
Asset Turnover	0.74
Inventory Turnover	2.73

Taxes

Income Tax	-1.79B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.44% in the last 52 weeks. The beta is 0.64, so KOREA PHARMA's price volatility has been lower than the market average.

Beta (5Y)	0.64
52-Week Price Change	-34.44%
50-Day Moving Average	11,179.80
200-Day Moving Average	12,887.75
Relative Strength Index (RSI)	29.72
Average Volume (20 Days)	25,982

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOREA PHARMA had revenue of KRW 91.42 billion and -2.47 billion in losses. Loss per share was -227.32.

Revenue	91.42B
Gross Profit	31.59B
Operating Income	-412.02M
Pretax Income	-4.27B
Net Income	-2.47B
EBITDA	2.71B
EBIT	-412.02M
Loss Per Share	-227.32

Balance Sheet

The company has 29.45 billion in cash and 39.77 billion in debt, with a net cash position of -10.32 billion or -946.34 per share.

Cash & Cash Equivalents	29.45B
Total Debt	39.77B
Net Cash	-10.32B
Net Cash Per Share	-946.34
Equity (Book Value)	68.93B
Book Value Per Share	6,363.34
Working Capital	8.43B

Cash Flow

In the last 12 months, operating cash flow was 5.10 billion and capital expenditures -18.95 billion, giving a free cash flow of -13.86 billion.

Operating Cash Flow	5.10B
Capital Expenditures	-18.95B
Depreciation & Amortization	3.13B
Net Borrowing	11.32B
Free Cash Flow	-13.86B
FCF Per Share	-1,270.48

Margins

Gross margin is 34.55%, with operating and profit margins of -0.45% and -2.70%.

Gross Margin	34.55%
Operating Margin	-0.45%
Pretax Margin	-4.67%
Profit Margin	-2.70%
EBITDA Margin	2.97%
EBIT Margin	-0.45%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.52%.

Dividend Per Share	50.00
Dividend Yield	0.52%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.33%
Shareholder Yield	0.84%
Earnings Yield	-2.48%
FCF Yield	-13.92%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOREA PHARMA has an Altman Z-Score of 2.58 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.58
Piotroski F-Score	3